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Abstract 
Gastrointestinal stromal tumours (GIST) are thought to originate from the interstitial cells of 
Cajal, which show many properties in common with neurons of the gastrointestinal tract. 
High-risk GIST has a very poor prognosis and tumour recurrence is common after 
intentionally curative surgery. With recent advances in our understanding of the molecular 
pathology of this disease and now that a specific KIT tyrosine kinase inhibitor, imatinib, is 
available, the prognosis for these patients has dramatically changed. 
A population-based study from western Sweden with a total population of approximately 
1.5 million was conducted, and 259 patients with clinically detected GIST were included. The 
annual incidence of GIST in the region was estimated to be 14.5 per million inhabitants. The 
majority of patients with high-risk GIST and all those with overtly malignant tumours 
experienced recurrence after complete (RO) resection. Tumour size, proliferative index (Ki67 
max%), RO resection, and KIT exon 11 deletion were independent prognostic factors. 
Prediction of prognosis for patients with GIST was simplified by a risk score based on tumour 
size and Ki67 max%. 
Early on, we treated patients with high-risk or overtly malignant GIST with imatinib in 
three different clinical settings (neoadjuvant, adjuvant and palliative) and response to 
treatment was found to be correlated with KIT mutational status and tumour regression. The 
response to treatment was studied by functional imaging of tumour glucose uptake using 18F-
fluorodeoxyglucose positron emission tomography (18F-FDG-PET). In one patient, 
neoadjuvant treatment facilitated later surgical treatment. Adjuvant imatinib seemed 
promising, but long-term effects on survival must be evaluated in randomised clinical trials. 
Palliative imatinib was safe and effective, particularly in patients with KIT exon 11 mutations. 
A 2-tracer PET, using 18F-FDG and 'C-hydroxyephedrine, was used to simultaneously 
detect GIST and pheochromocytoma in patients with neuroendocrine (NE) tumour 
syndromes, e.g. Carney triad and neurofibromatosis type 1. 
GISTs were examined for a possible NE phenotype by immunohistochemistry, western 
blot and quantitative gene expression studies. GIST showed an abundant expression of 
synaptic-like microvesicle (SLMV) proteins both at the transcriptional and the translational 
level. Subsets of GIST appear to express peptide hormone receptors, which may be used for 
receptor-based radionuclide therapy. 
In summary, the incidence of GIST was shown to be higher than previously estimated. 
Radical surgery and KIT exon 11 mutation were important prognosticators. Adjuvant 
treatment with imatinib seems to be promising in patients with high-risk GIST. Pre-treatment 
with imatinib is an attractive option in patients with tumours that are non-resectable initially. 
The 2-tracer PET technique may be useful in patients with NE tumour syndromes. The 
expression of SLMV proteins in GIST indicates a certain degree of NE differentiation, which 
has possible potential therapeutic implications. 
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neuroendocrine phenotype, PET, prognosis, surgery, vesicle proteins. 
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staining of GIST by CD117 (top right). Molecular structure of imatinib mesylate 
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ABBREVIATIONS 
ATP adenosine triphosphate 
CD117 KIT antibody 
Cg chromogranin 
CT computed tomography 
ddH20 double-distilled water 
dHPLC denaturating high-performance liquid chromatography 
DNA deoxyribonucleic acid 
18F-FDG 18F-fluorodeoxyglucose 
GI gastrointestinal 
GIST gastrointestinal stromal tumour 
HED hydroxyephedrine 
hpf high-power field 
HRP horseradish peroxidase 
ICC interstitial cells of Cajal 
i.v. intravenous 
LDCV large dense-core vesicle 
MAP mitogen-activated protein 
MBq megabecquerel 
mc monoclonal 
MRI magnetic resonance imaging 
NF1 neurofibromatosis type 1 
pc polyclonal 
PCR polymerase chain reaction 
PDGFRA platelet-derived growth factor receptor alpha 
PET positron emission tomography 
PI3K phosphatidylinositol 3-kinase 
Q-PCR quantitative reverse transcriptase polymerase chain reaction 
RO no residual tumour 
R1 microscopic residual tumour 
R2 macroscopic residual tumour 
RECIST response evaluation criteria in solid tumours 
SCF stem cell factor 
SLMV synaptic-like microvesicle 
SMA smooth-muscle actin 
SNOMED systematised nomenclature of medicine 
SV2 synaptic vesicle protein 2 
VMAT vesicular monoamine transporter 
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INTRODUCTION 
Historical Aspects 
In the past, gastrointestinal stromal tumours (GISTs) were thought to be of smooth-
muscle origin (Golden & Stout, 1941) and consequently classified as leiomyomas, 
leiomyosarcomas, or leiomyoblastomas (Appleman, 1986). Ultrastructural studies in 
the 1960s and 1970s did not give consistent evidence of smooth-muscle differentiation 
in GIST (Franquemont, 1995). With the introduction of immunohistochemistry, it was 
shown that the expression of smooth-muscle markers, i.e. actin and desmin, was 
highly variable in these tumours. Mazur & Clark (1983) introduced the term "stromal 
tumour" to describe this heterogeneous tumour entity. A subset of stromal tumours 
stained positively for neural crest markers (S-100, neuron-specific enolase) not found 
in other smooth-muscle neoplasms (Franquemont, 1995). Gastrointestinal autonomic 
nerve tumours (GANT) were described as a phenotypic variant of GIST with 
neuroendocrine (NE) differentiation (Miettinen et al., 1999). 
With the finding that most gastrointestinal (GI) stromal tumours are positive for 
CD34, a glycoprotein normally expressed on endothelial cells and hematopoietic stem 
cells, the term GIST became more widely used (Miettinen et al., 1995). Today, GISTs 
are regarded as the most common mesenchymal (non-epithelial) neoplasms of the GI 
tract. True smooth-muscle tumours, i.e. leiomyoma and leiomyosarcoma, are rare in 
the GI tract (Miettinen & Lasota, 2001). 
Definition of GIST 
The lack of smooth-muscle differentiation combined with occasional neural 
characteristics in GIST led to speculation that these stromal tumours were related to 
the interstitial cells of Cajal (ICC), a network of spindle-shaped cells in the intestinal 
wall (Perez-Atayde et al., 1993). ICC are intercalated between gut smooth-muscle 
cells and nerve terminals (Faussone-Pellegrini, 1990), where they function as 
regulators of intestinal peristalsis and mediators of neurotransmission (Sanders, 1996). 
The observation that the tyrosine kinase receptor KIT is expressed by ICC and is of 
vital importance for the development of these cells (Huizinga et al., 1995) led to the 
discovery that GISTs also express KIT. Due to the striking similarities between GIST 
cells and ICC, it is currently believed that GISTs originate from precursor cells that 
may differentiate towards ICC (Kindblom et al., 1998). The KIT protein, detected 
immunohistochemically by CD117 (antibody to KIT), is expressed in the vast majority 
of GISTs. CD 117 is presently regarded as a sensitive and specific marker for these 
tumours (Hornick & Fletcher, 2002). 
The histological appearance of GISTs is quite variable. About two-thirds of the 
tumours are composed of spindle-shaped cells or epithelioid cells, but mixed spindled-
epithelioid tumours and tumours with NE features also occur. Typically, GISTs stain 
positive for KIT (CD117) in 95% of cases, CD34 in 70%, smooth-muscle actin (SMA) 
in 35%, S-100 in 5% of cases, but rarely for desmin (Miettinen & Lasota, 2001). 
GISTs are currently defined as intra-abdominal mesenchymal tumours that express the 
KIT protein, or have KIT- or PDGFRA mutations (see Molecular Pathology section). 
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Recent studies have demonstrated strong expression of a novel protein, DOG-1 (West 
et al., 2004), and protein kinase C theta (PKC0), a molecule associated with T-cell 
activation and neural differentiation (Blay et al., 2004). Gene expression studies have 
revealed the secretory granule NE protein 1 and chromogranin C (CgC) in GIST, 
which may indicate a possible NE differentiation (Buragas et al., 2005). 
It is important to correctly diagnose GIST, since these patients can be offered 
several therapeutic options. The main differential diagnoses are other intra-abdominal 
soft-tissue tumours (Table 1). 
Table 1. Differential diagnosis of gastrointestinal stromal tumours (GIST).  
KIT CD34 SM A S-100 Desmin 
GIST + 60-70% 30-40% 5% Rare 
Smooth-muscle - 10-15% + Rare + 
tumour 
Schwannoma - + - + -
Fibromatosis Disputed Rare + - Rare cells 
Modified from Fletcher et al. (2002). 
Clinical Features 
Due to difficulties in classification, the true incidence of GIST is unknown. Previous 
reports have estimated the annual incidence to be approximately 4 per million 
inhabitants (DeMatteo et al., 2000; Jemal et al., 2002). GIST has an equal sex 
distribution, and the median age at presentation is about 60 years. The majority of 
GISTs are sporadic, but individuals from the same family with GIST have been 
reported (Nishida et al., 1998; Beghini et al., 2001). GISTs have also been associated 
with certain syndromes including NE tumours, i.e. Carney triad and neurofibromatosis 
type 1 (NF1, von Recklinghausen's disease) (Zöller et al., 1997; Carney, 1999). There 
have also been case reports on multiple GIST and synchronous ileal carcinoids 
(Buragas et al., 2005). 
GISTs are most commonly seen in the stomach and small intestine, but can also 
originate in the oesophagus, the colo-rectum, mesentery, omentum, and 
retroperitoneum. Since GISTs tend to grow non-invasively, the tumours can be large 
before they cause symptoms. The vast majority of GISTs are solitary and well-
delineated at diagnosis. 
The clinical presentation is often related to tumour size; smaller tumours are found 
incidentally during endoscopy, radiological imaging, or surgery for other reasons. 
Larger tumours are usually diagnosed during work-up for symptoms. In reports from 
tertiary cancer centres, it has been shown that up to 50% of GISTs are metastatic at 
presentation (DeMatteo et al., 2000; Crosby et al., 2001). 
In general, GIST recurs within the abdominal cavity, and frequently involves the 
peritoneum (52%), the liver (63%), or both (15%) (Ng et al., 1992b; DeMatteo et al., 
2000). Extra-abdominal metastases (pulmonary and bone) are rare but can occur late in 
disease. Lymph node metastases are very rare (Fong et al., 1993). 
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Diagnosis 
With growing awareness of this tumour type in recent years, there has been 
considerable interest in establishing early diagnosis. On CT/MR1, GIST should be 
suspected when there is a well-defined mass closely associated with the stomach or 
intestine. Intra-tumoural necrosis, or haemorrhage, strengthens the suspicion. CT/MRI 
are essential investigations to determine the extent of the primary tumour 
anatomically, multicentricity, and presence of metastases. Endoscopy may identify 
submucosal lesions, with or without ulceration. On endoscopic ultrasound, GISTs are 
characterised by a marginal halo and relatively high echogenicity, and can therefore 
often be distinguished from leiomyomas or leiomyosarcomas (Okai et al., 2003). 
The role of functional imaging by positron emission tomography (PET) is rapidly 
expanding. GISTs, like several other malignancies, have increased glucose metabolism 
and thus take up the tracer 18F-fluorodeoxyglucose (FDG). This technique can be used 
for staging of the tumour disease and is of value for planning of the surgical approach 
(van den Abbeele & Badawi, 2002). It was recently reported that tumour uptake on 
I8F-FDG-PET was very rapidly extinguished (within 24^8 hours) in response to 
treatment with imatinib (Stroobants et al., 2003). When PET was combined with 
another imaging modality such as CT (PET-CT), the accuracy of diagnosing and 
monitoring treatment responses in GIST was further improved (Antoch et al., 2004). 
Prognostic Features 
GISTs represent a spectrum of disease that ranges from benign tumours with excellent 
prognosis to highly malignant tumours with very poor prognosis. The clinical 
behaviour has not always been easy to predict, and several prognostic factors have 
been proposed. 
The most frequently used prognostic parameters for GIST have been tumour size 
and mitotic rate. During an NIH/NCI-workshop, consensus guidelines were prepared 
that emphasised the importance of tumour size and mitotic index in estimating the 
metastatic risk of primary GIST (Fletcher et al., 2002) (Table 2). 
Table 2. Risk assessment of primary GIST.  
Risk Size (cm) Mitotic Count (per 50 hpf) 
Very low risk <2 <5 
Low risk 2-5 <5 
Intermediate risk <5 6-10 
5-10 <5 
High risk >5 >5 
>10 Any mitotic rate 
Any tumour > 10 
Modified from Fletcher et al. (2002). 
Surgery 
Complete (R0) surgical resection provides the best chance of cure in patients with 
GIST. Only a localised resection of the tumour, i.e. wedge resection of the stomach or 
a segmental intestinal resection, is necessary for well-delineated tumours. Negative 
microscopic margins must be attempted. If necessary, en-bloc resection of adjacent 
organs should be considered. Avoidance of tumour rupture is imperative (Ng et al, 
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1992a). Some authors have recommended wide peritoneotomy because of the high risk 
of peritoneal recurrence (Roberts & Eisenberg, 2002). The value of regional lymph-
node resection is unproven, and extensive lymphadenectomy is not recommended 
(Fong et al., 1993; DeMatteo et al., 2002). In recent years, laparoscopic resection has 
been advocated for smaller gastric GISTs (Hindmarsh et al., 2005). This technique 
seems appropriate, but the present series are limited in size and long-term follow-up 
data are lacking. 
Chemotherapy and Radiation Therapy 
Systemic chemotherapy has been largely unsuccessful in GIST patients. The frequency 
of partial responses after either single-agent therapy or combination therapy has varied 
between 0 and 15% (DeMatteo et al., 2002; De Pas et al., 2003). One explanation may 
be that GISTs have increased levels of multidrug resistance proteins in comparison 
with leiomyosarcomas (Plaat et al., 2000). Intraperitoneal chemotherapy was 
introduced to improve the results after surgery for peritoneal recurrence. However, it 
did not alter survival for patients with liver metastases, but it probably contributed to 
extending the mean time to recurrence from 8 to 21 months (Eilber, 1999). The 
experience of radiation therapy in GIST is limited; in one report, radiation therapy 
temporarily controlled metastatic GIST in 6 out of 9 patients (Crosby et al., 2001). 
Molecular Pathology 
The KIT gene, located on chromosome 4qll-ql2 (Spritz et al., 1994), has 21 exons 
and is the cellular homologue of the oncogene v-kit of the Hardy-Zuckerman feline 
sarcoma virus (Besmer et al., 1986). It encodes the tyrosine kinase receptor KIT 
(CD 117), which is of fundamental importance in the pathogenesis of GIST. KIT 
belongs to the subclass III family of tyrosine kinase receptors, which is closely related 
to the receptors for platelet-derived growth factor (PDGF), macrophage colony-
stimulating factor, and FLT3 ligand (Rousset et al., 1995). KIT is a transmembrane 
receptor in which the extracellular region has a binding site for the ligand: stem cell 
factor (SCF). The intracellular region consists of an ATP-binding site and a split 
tyrosine kinase domain (Fig. 1 A). KIT is expressed by haematopoietic cells, 
melanocytes, mast cells, germ cells, and ICC (Heinrich et al., 2002), and is important 
for differentiation, cell growth and survival. The unbound KIT protein is 
enzymatically inactive. It is activated by the binding of bivalent ligand dimers, i.e. two 
adjacent receptors are brought together in a process called homodimerisation, which 
results in activation of kinases and cross-phosphorylation of intracellular tyrosine 
residues (Broudy, 1997; Nishida & Hirota, 2000) (Fig. 1 A). The phosphorylation of 
KIT and PDGFRA activates similar downstream molecules: mitogen-activated protein 
(MAP) kinase, AKT, mTOR, p70/85S6K, STAT 1 and STAT 3 (Heinrich et al., 
2003b; Duensing et al., 2004). The phosphorylation is mainly mediated via the PI3 
kinase/AKT/mTOR pathways (Fig. 1 A and B), and inhibition of the PI3 
kinase/mTOR pathway reduces proliferation and increases apoptosis (Duensing et al., 
2004). 
KIT Mutations. The vast majority of sporadic GISTs have gain-of-function mutations 
in KIT (Hirota et al., 1998; Rubin et al., 2001; Corless et al., 2002; Heinrich et al., 
2003a) that result in ligand-independent dimerisation, autophosphorylation and 
12 
activation of downstream signalling pathways. The mutations are confined to only 4 
exons; exon 9 encoding the extracellular transmembrane domain, exon 11 encoding 
the intracellular juxtamembrane domain, exon 13 encoding the the first portion of the 
kinase domain, and exon 17 encoding the second portion of the kinase domain (Fig. 1 
B) 
Sixty to seventy per cent of the mutations involve exon 11, a domain that 
normally functions by inhibiting receptor dimerisation in the absence of SCF, thus 
leading to ligand-independent receptor activation. Most exon 11 mutations are 
deletions and/or point mutations located at the 5' end (Heinrich et al., 2003a). 
Exon 9 mutations are found in approximately 10% of cases. This type of mutation 
is interesting, since all but one of such mutations were found by Antonescu et al. 
(2003) to be identical (an insertion of 6 nucleotides resulting in duplication of alanine 
501 and tyrosine 502) and almost all mutations were found in small intestinal GISTs. 
Mutations in exon 13 (kinase 1 domain) and exon 17 (kinase 2 domain or 
activation loop) have been seen in about 1% and < 1% of cases, respectively (Lasota et 
al., 2000; Lux et al., 2000; Rubin et al., 2001). 
Even in the absence of a mutation, nearly all GISTs express a phosphorylated KIT 
protein, indicating that they are constitutively activated (Rubin et al., 2001). 
Explanations for this could be an alteration in related proteins, gene amplification, or 
different methylation patterns (DeMatteo et al., 2003). Mutations of KIT do not occur 
in l eiomyomas or leiomyosarcomas (Lasota et al., 1999). The KIT mutation is almost 
always somatic, but several family members with heritable mutations of exon 11 have 
been identified. The familial cases often have multiple and small tumours; they also 
display a diffuse hyperplasia of the Auerbach's plexus. In addition, many patients with 
familial GIST have systemic cutaneous hyperpigmentation. Abnormalities of mast 
cells have been reported, e.g. urticaria pigmentosa or systemic mast cell disease 
(Longley et al., 1996). Clinical features and mutation analysis in families with 
inherited exon 11 mutations indicate an association between ICC 
hyperplasia/neoplasia, multiple GISTs, melanocytic dysfunction, and cutaneous mast 
cell proliferation (Nishida et al., 1998; Hirota et al., 2000; Beghini et al., 2001; 
Maeyama et al., 2001). 
PDGFRA Mutations. A small subset of GIST patients with no mutation in KIT can 
have mutations in the PDGFRA gene (Heinrich et al., 2003b; Hirota et al., 2003). The 
mutations involve exons 12, 14, and 18, which are homologous to KIT exons 11, 13, 
and 17. The signal transduction profiles for these PDGFRA-mutant tumours were 
found to be the same as for KIT-mutant tumours, suggesting that PDGFRA can have a 
role similar to that of KIT in GIST oncogenesis (Heinrich et al., 2003b). The majority 
of PDGFRA-mutant tumours express KIT only weakly, or not at all. These tumours 
are often gastric in origin and associated with a fairly benign clinical course (Lasota et 
al., 2004; Miettinen et al., 2005). About 5-10% of GISTs lack both KIT and PDGFRA 
mutations. 
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Fig. 1. A. Ligand-induced dimerisation of KIT or PDGFRA results in autophosphorylation and 
activation of downstream signalling involved in cell differentiation, cell proliferation, and cell 
survival. B. Independent dimerisation, due to gain-of-function mutations in the KIT or PDGFRA 
genes, results in unrestrained cell proliferation. 
Imatinib 
Imatinib mesylate (Glivec®, Novartis Pharmaceuticals, Basel, Switzerland)-initially 
developed to inhibit ABL as treatment for chronic myelogenous leukaemia-has caused 
a paradigm shift in cancer therapy. Imatinib is an ATP analogue that binds to the 
intracellular portion of KIT. In this way, the kinase is prevented from transferring 
phosphate groups from ATP to tyrosine residues of substrates. This inhibits 
downstream signalling from the kinase and switches the balance between cell 
proliferation and apoptosis towards apoptosis (Fig. 2). 
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Imatinib selectively inhibits several tyrosine kinases, including ABL, BCR-ABL 
fusion protein, KIT and PDGFRA (Carroll et al., 1997). Imatinib is well absorbed after 
oral administration. The half-life is about 20 hours (Druker et al., 2001; Demetri et al., 
2002), which is compatible with once-daily administration. Preclinical studies have 
shown that imatinib serum concentrations of greater than l umol/L are necessary for 
optimum therapeutic effects, which can be achieved by daily doses of > 300 mg. 
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AIMS OF THE STUDY 
The epidemiology, prognostic factors and outcome of the surgical treatment of GIST 
have not been addressed in population-based studies. With the introduction of the 
tyrosine kinase inhibitor imatinib, effective treatment of GIST became possible. 
Functional imaging with 18F-FDG-PET has turned out to be a valuable tool for 
evaluation of tumour responses to treatment with imatinib. GISTs are thought to 
originate from ICC, which show properties in common with neurons of the GI tract. 
The aims of the study were: 
o To analyse the incidence and prevalence of GIST and to validate both the 
consensus risk stratification scheme and a new risk score based on tumour size 
and proliferative index (I). 
o To evaluate radical surgery (RO resection) and other prognostic factors in a 
population-based patient series with long follow-up (II). 
o To explore the usefulness of imatinib in d ifferent clinical settings (neoadjuvant, 
adjuvant and palliative) and evaluate response to given treatment with respect to 
KIT exon 11 mutational status (III). 
o To demonstrate the diagnostic value of a novel 2-tracer PET technique in patients 
with GIST as part of NE tumour syndromes (IV). 
o To evaluate NE differentiation in GIST by analysing the expression of synaptic 
vesicle proteins (V). 
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MATERIALS & METHODS 
Population-Based Studies (papers I & II) 
Retrieval of Patients 
Records on all potential patients with GIST, diagnosed between January 1983 and December 2000 
within the Swedish region of Västra Götaland (population 1.3-1.6 million), were retrieved. 
Histopathological examination of all patients was performed in four hospital-based pathology 
laboratories, each covering a defined geographic area. Computerised files of histopathological 
diagnoses according to the topographic and morphological (T and M) coding system of SNOMED 
were used to retrieve all patients. T codes included all sites in the GI tract; intra-abdominal, 
retroperitoneal, mesenteric, omental and pelvic areas, and the liver. M codes included all benign and 
malignant mesenchymal lesions, tumours of the autonomic and peripheral nervous systems, and 
benign and malignant tumours not further classified. In all 1,460 patients who matched the T and M 
codes, clinical information and pathology reports were reviewed. Five hundred patients were excluded 
immediately, since they obviously did not have GIST. In the remaining 960 patients, slides were 
reviewed histologically, after which 310 other patients had to be excluded. The remaining 650 patients 
were studied in detail including immunohistochemical analyses. 
Inclusion Criteria 
Requirements for the diagnosis of GIST and inclusion in these studies were: (1) site in or adjacent to 
the GI tract, mesentery, omentum, or retroperitoneum; (2) spindle-shaped and/or epithelioid 
morphology compatible with GIST; and (3) positive immunoreactivity for CD117. Three hundred and 
ninety-eight of the 650 patients fulfilled these criteria. Ninety-five patients were excluded because 
they were referrals from other regions, and 15 patients were excluded because they had a primary 
GIST diagnosed before 1983. Two hundred and eighty-eight patients with primary GIST from our 
region remained and were included in paper I. For the analyses in paper II, 29 patients with autopsy-
based diagnosis were excluded; 259 patients with clinically detected primary GIST were thus studied. 
Morphological Analysis 
The following data were recorded for each patient: histological type, degree of tumour cell 
pleomorphism, mitotic rate per 50 high-power fields (hpf, with 1 hpf =0.16 mm2), average and 
maximum proliferative index (Ki67), and patterns of immunoreactivity for CD117 and CD34. The 
following antibodies were used: CD117 (pc), CD34 (mc), and Ki-67 (MIB1; mc) (paper I). 
Clinical Information and Follow-up 
Information regarding presenting symptoms and dates of diagnosis, tumour status at diagnosis, 
treatment, and diagnosis of local recurrences or metastases were recorded. For all patients, information 
on survival and cause of death was obtained from clinical records, autopsy reports and Official 
Population Registries. Surgical margins were assessed from clinical records and evaluation of the 
histological findings in the specimens. The margins were classified as R0 (no residual tumour), R1 
(microscopic residual tumour), and R2 (macroscopic residual tumour) according to UICC (TNM 
classification of malignant tumours, 2002). All tumours were classified according to a consensus risk 
group stratification system based on tumour size and mitotic rate per 50 hpf (Fletcher et al., 2002; 
Table 2). In these studies, we added a fifth group called overtly malignant, which included all patients 
with proven metastatic disease at diagnosis. The median follow-up time of surviving patients was 8 
years (range 1.8-19.5 years) (paper II). 
Statistical Analysis 
A Poisson regression model (Breslow & Day, 1987) was used for the analysis of overall survival 
instead of the Kaplan-Meier model, because the latter cannot treat continuous risk variables efficiently 
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and d oes not allow all types of comparisons with the normal population. This model was used to 
calculate the survival function for the different risk groups according to Fletcher et a l. (2002), with 
addition of the overtly malignant group. In the analysis, the follow-up was divided in intervals of 0.5 
years, and the death rate within each interval was estimated by calculating the quotient between the 
number of events and patient years within the interval. From this, a stepwise constant hazard function 
was obtain ed and, by applying the mathematic relation between survi val and hazard functions, the 
survival function was determined. The expected proportion of survivors was calculated, taking age, 
sex, and calendar time into account using the mathematical relations applied to hazard functions 
derived from official statistics of Sweden. Continuous variables were compared using the non-
parametric Mann-Whitney U test and categorical variables using F isher's exact test. In the analysis of 
all prognostic factors in paper I, the Poisson regression (Breslow & Day, 1987) was used to estimate a 
hazard function of the form exp (ßo + ß\xX\+...), where the ß values were coefficients and Xi, i = 1, 2, 
were variables. The function was continuous as a function of all con tinuous variables, including 
time since diagnosis. The analysis was performed by a stepwise procedure, which, at the end, only 
included variables that were significant in the multivariate context. The Poisson regression analysis 
resulted in a risk score, which was a linear combination defined by the variables and the ß coefficients. 
A special analysis was performed to elucidate how well the risk score captured the large variation in 
the risk of dying. The probability of dying within 5 years after diagnosis was calculated depending on 
the risk score. The calculation of the percentile points was based on a piecewise linear transformation 
of the score yielding a normally distributed variable. Regression on age was applied to the normally 
distributed variable. The incidence of GIST was calculated from the number of clinically detected 
primary GIST cases divided by the accumulated number of person years (17,862,068) during the 
period 1983-2000. The prevalence was calculated from the age specific incidence figures and the 
estimated death hazard function, taking into account risk groups and calendar time. 
In paper II, disease-free survival time was calculated as the interval from the initial diagnosis to 
the diagnosis of recurrence, persistent disease, or tumour-related death. Recurrence-free survival time 
was calculated as the interval from the initial diagnosis to the diagnosis of the first recurrence. Patients 
with no evidence of recurrence at last follow-up and those who died from non-GIST causes were 
censored in the analysis of disease-free survival. Patients without evidence of recurrence or metastasis 
at last follow-up were censored and those with persistent disease were excl uded from the analysis of 
recurrence-free survival. Survival estimates in paper II were calculated by the Kaplan-Meier method 
and differences between g roups were compared by the log rank test. As in paper I, stepwise Poisson 
regression procedures were used to estimate the hazard functions for recurrence and tumour-related 
death, and to identify independent risk factors. All statistical tests were two-sided. P < 0.05 was 
considered statistically significant. 
New Therapeutic Options Combining Surgical and Medical Treatment 
(paper III) 
Patients 
Seventeen consecutive patients with high-risk, or overtly malignant, GIST were admitted to 
Sahlgrenska University Hospital from May 2001 to September 2002, and included in this study. There 
were two females and 15 males, with a median age at primary surgery of 62 years (range 10-74 years). 
One patient with initially non-resectable GIST was treated neoadjuvantly with imatinib so that 
surgical treatment could be performed later. Three out of 5 patients were treated with adjuvant 
imatinib after R1 resection for rectal GIST: two had primary tumours and the other a local recurrence. 
All three patients had no clinical or radiological signs of residual tumour after surgery; however, all 
had microscopic intra-lesional margins. A fourth patient with a small intestinal GIST also had intra-
lesional margins (observed 4 months). The fifth patient, a young female, had a gastric GIST (observed 
144 months). She was first operated upon at age 10, and had then, during a 12-year period prior to 
imatinib, undergone 5 operations due to recurrence. Eleven patients received palliative imatinib, 10 
due to unresectable primary tumour, peritoneal and/or liver metastases, and one due to pulmonary 
metastases. 
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Morphological Analysis 
All resected or biopsied tumours were reviewed histologically. Histologically, three (18%) of the 
tumours were predominantely epithelioid, 8 (47%) were predominantely spindle-shaped, and 6 (35%) 
mixed spindle-shaped and epithelioid. The mitotic rate per 50 consecutive hpfs was recorded as < 2, 
2-5, 6-10, and > 10 per 50 hpfs. Proliferative activity was assessed visually, estimating the percentage 
of Ki67-immunopositive tumour cells using MIB1. Immunostains for CD117, CD34, a-SMA, desmin, 
and S100 protein were performed in all 17 cases and found to be positive in 17 (100%), 14 (82%), two 
(12%), zero, and zero cases, respectively. 
Clinical Information and Follow-up 
Treatment with imatinib, 400 mg p.o. once-daily, was given neoadjuvantly (n = 1) three months prior 
to surgery, adjuvantly (n = 5) over 7-13 months, or palliatively (n = 11) over 6-18 months. Side 
effects were monitored in agreement with the US National Cancer Institute Common Toxicity Criteria 
(version 2.0). Tumour response was evaluated by spiral CT (5-mm contiguous reconstruction 
algorithm) 3, 6, and 12 months after induction of imatinib, and categorised according to the RECIST 
(Therasse et al., 2000). MRI (contiguous cuts of 10 mm or less) was performed in the patient who 
received neoadjuvant therapy. 18F-FDG-PET was performed before and during treatment with imatinib 
in 10 patients. 
New Imaging Options (paper IV) 
Patients 
In this study we reported two patients with NE tumour syndromes, one with complete Carney triad and 
one with NF 1, in whom accurate diagnosis of both pheochromocytoma and GIST in the same patient 
was made by a sensitive 2-tracer PET technique. 
PET 
Attenuation-corrected whole-body PET with a dedicated scanner (CTI/Siemens) was performed 10 
min after i.v. injection (800 MBq) of uC-hydroxyephedrine (HED) to visualise regional catecholamine 
accumulation and 1 hour after i.v. injection (400 MBq) of 18F-FDG to visualise regional glucose 
uptake. Both examinations were performed on the same day. All images were corrected for attenuation 
and iteratively reconstructed with a 6-mm Hann filter. All post-processing was done with standard 
software supplied by the manufacturer. 
Immunohistochemistry 
The following monoclonal and polyclonal antibodies directed against the following proteins were 
used: CD117 (pc), CgA (pc), tyrosine hydroxylase (pc), vimentin (mc), SMA (mc), S-100 (pc), and 
Ki67 (MIB1; mc). All slides were subjected to antigen retrieval by microwave treatment. Bound 
antibodies were visualised by indirect immunoperoxidase techniques (Dako EnVision+). 
Neuroendocrine Differentiation in GIST (paper V) 
Tumours 
Forty-one tumours obtained from the population-based material (papers I & II) were studied by 
immunohistochemistry. Tumours were separated into low-risk profile GIST (very low-risk, low-risk 
and intermediate-risk; n = 29) and high-risk profile GIST (high-risk and overtly malignant; n = 12). In 
low-risk profile tumours, 27 primaries, one local recurrence and one metastasis were used for analysis. 
In high-risk profile tumours, 7 primaries, one local recurrence and 4 metastases were used. 
Biopsies from 10 patients with GIST were analysed by western blot: four patients with low-risk 
profile tumours and 6 patients with high-risk profile tumours. In low-risk profile tumours, only 
primaries were used for analysis. In high-risk profile tumours, one primary, one local recurrence and 4 
metastases were used. 
Biopsies from 10 patients with GIST were analysed by quantitative reverse transcriptase 
polymerase chain reaction (Q-PCR). There was equal distribution between low-risk and high-risk 
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profile tumours. In low-risk profile tumours, 4 primaries and one local recurrence were used for 
analysis. In high-risk profile tumours, one primary, one local recurrence and 3 metastases were used. 
Immunohistochemistry 
Tissue sections from paraffin-embedded specimens were placed on positively-charged slides, 
deparaffinised, rehydrated, and subjected to antigen retrieval by microwave treatment. Incubation with 
primary antibodies (Table 3) was followed by detection with DakoCytomation EnVision+ System-
HRP labelled polymer or DakoCytomation LSAB®+ System-HRP. Diaminobenzidine was used as a 
chromogen. After counterstaining, sections were dehydrated and mounted. Immunolabelling was 
graded as: 0 = < 1% positive tumour cells; 1+ = 1-24% positive tumour cells; 2+ = 25-75% positive 
tumour cells; 3+ = > 75% positive tumour cells. 
Western Blot 
Frozen tumour tissues (200 mg/sample) were homogenised in 10 mM potassium phosphate buffer, pH 
6.8, containing 1 mM EDTA, 9.8 mM 3-(3-cholamidopropyl) dimethylammonium 1-propane sulphate 
and protease inhibitors. Homogenates were sonicated, followed by centrifugation and assay for protein 
content. Aliquots of proteins (40 pig) w ere electrophoresed on Polyacrylamide gels (10% NuPAGE 
Bis-Tris gels; Invitrogen). Proteins were transferred to polyvinyl difluoride membranes using a 
NOVEX blotting system. Membranes were incubated with primary antibodies (Table 3) at 4°C 
overnight, followed by alkaline phosphatase-conjugated secondary antibodies and CDP-star (Tropix) 
as substrate. Membranes were then exposed to ECL film at room temperature. Molecular weight 
markers (See-Blue Plus 2 and MagicMark; Invitrogen) were used to calculate the apparent sizes of 
immunoreactive proteins. 
Table 3. Antibodies used for immunohistochemistry and western blot. 
Antibody  
Amphiphysin (mc) 
B-actin (mc) 
CD 117 (pc) 
CgA (mc) 
GAP 43 (mc) 
SNAP 25 (mc) 
SV2 (mc) 
Synapsin 1 (mc) 
Synapsin 2A (mc) 
Synaptobrevin (mc) 
Synaptophysin (mc) 
Syntaxin (mc) 
VMAT 1 (pc) 
VMAT 2 (pc) 
mc, monoclonal; pc, polyclonal. 
Q-PCR 
RNA Extraction. Total RNA was prepared by homogenising tumour biopsies in Trizol Reagent 
(Invitrogen) using a Tissuelyser (Qiagen) followed by RNA purification using the FastRNA kit (QBIO 
Species Clone Code No. Source 
Mouse 3 VAM-SV030 Nordic Biosite AB, 
Täby, Sweden 
Mouse MAbcam 
8226 
AB8226 Abeam Ltd., 
Cambridge, UK 
Rabbit " A4502 DakoCytomation Denmark A/S, 
Glostrup, Denmark 
Mouse LK2H10 MAB319 Chemicon International, Inc., Temecula, 
CA, USA 
Mouse IG7 NCL-GAP43 Novocastra Laboratories Ltd., 
Newcastle upon Tyne, UK 
Mouse SP12 NB09 Oncogene'" Research Products, 
Darmstadt, Germany 
Mouse SP2/0 SV2 Developmental Studies Hybridoma 
Bank, Iowa city, IA, USA 
Mouse A10C NB08 Oncogene'" Research Products, 
Darmstadt, Germany 
Mouse 1 S56820 Transduction Laboratories, 
Lexington, KY, USA 
Mouse SP10 MMS-616R Nordic Biosite AB, 
Täby, Sweden 
Mouse SY38 M0776 DakoCytomation Denmark A/S, 
Glostrup, Denmark 
Mouse SP8 MAB336 Chemicon International, Inc., 
Temecula, CA, USA 
Goat 
-
Sc-7718 Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA 
Rabbit 
-
AB1767 Chemicon International, Inc., 
Temecula, CA, USA 
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gene). RNA yields were measured by reading absorbance at 260 nm (Nano Drop ND-1000). The 
quality of extracted RNA was examined by gel electrophoresis (Agilent 2100 Bioanalyzer). Before 
cDNA-synthesis, 4 pg of total RNA per sample was subjected to DNase treatment using DNA-Free 
(Ambion). 
cDNA Synthesis. cDNA was synthesised from extracted RNA using TaqMan reverse transcription 
reagents with random hexamers (Applied Biosystems). From each tumour sample, 0,4 pg RNA was 
used for the cDNA synthesis, and a control reaction without reverse transcriptase was run. 
Primers and Probes. Primers and probes against synaptobrevin 1 & 2 (VAMP 1 & 2), amphiphysin 
(AMPH), synapsin 1 (SYN 1), synaptic vesicle protein 2A (SV2A), KIT (KIT), chromogranin A 
(CHGA), synaptophysin (SYP), VMAT 1 & 2 (VMAT 1 & 2) and ß-actin were purchased from 
Applied Biosystems. 
Real-Time PCR Assay. The PCR assays were performed in 96-well optical plates, using an ABI Prism 
700. The reaction consisted of 40 cycles of 90°C for 15 sec and 60°C for 1 min. Samples were 
analysed in triplicate. The cycle threshhold (Ct) for the target gene and ß-actin were determined for 
each sample. Values were expressed as - ACt (t arget gene - ß-actin) or number of target copies per 
1,000 copies of ß-actin. 
Mutation Analysis (papers II-V) 
DNA/RNA Isolation and Amplification 
Genomic DNA was extracted from formalin-fixed, paraffin-embedded archival tumour tissue and 100 
ng was amplified in 50 pi PCR reactions using BD Advantage 2 or BD Sprint (Clonetech, BD 
Biosciences) according to the manufacturer's recommendations with primers designed to amplify KIT 
exons 9, 11, 13, and 17 as well as PDGFRA exons 12 and 18, respectively. Total RNA was extracted 
from fresh-frozen tumour tissue and used as template in the cDNA synthesis. cDNA was amplified in 
100 pi PCR reactions with primers PCRKIT21s and PCRKIT22as designed to amplify exon 11 of the 
KIT gene. 
Denaturing High-Performance Liquid Chromatography and Nucleotide Sequence Analysis 
Denaturing High-Performance Liquid Chromatography (dHPLC) is a rapid and sensitive method for 
screening for mutations within DNA samples, and was used in paper II. This technique is based on 
liquid chromatography in a column where a stationary phase is used to retain samples and a mobile 
phase is used to release samples from the column. In WT DNA (no mutation), the alleles in the sample 
form two homoduplexes. In contrast, in samples with mutation, there is a mismatch and both homo-
and heteroduplexes are formed. Heteroduplexes have a weaker affinity for the stationary phase than 
homoduplexes and are therefore eluted from the column at lower concentrations of the mobile phase. 
Heteroduplex formation was carried out by denaturing the PCR products at 95°C, and then allowing 
the samples to re-anneal by gradually decreasing the temperature to 45°C. 5-10 pi of the PCR product 
was injected on a Helix DNA HPLC Column 50 x 3.0 mm (Varian) and eluted at a flow rate of 0.45 
ml/min. Samples showing an aberrant elution profile were re-extracted, re-amplified and the mutated 
sequence was then determined by bidirectional direct sequencing using the same primers as in the 
PCR reactions. 
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RESULTS AND DISCUSSION 
Population-Based Studies (papers I & II) 
Incidence and Prevalence 
The true incidence and prevalence of GIST is still controversial. The reason for this 
has been the absence of well-defined pathological criteria, variable nomenclature over 
time, and the fact that the majority of such tumours have been diagnosed as benign or 
as tumours of uncertain malignant potential. Under such circumstances, some of these 
tumours may not have been reported to the National Cancer Registries. Our approach-
to review all mesenchymal and nervous system GI tumours histopathologically from a 
well-defined population over a long period of time-gives a unique opportunity to 
estimate incidence/prevalence of authentic GIST. The annual incidence of clinically 
detected GIST in our region was estimated to be 14.5 per million inhabitants (95% CI: 
12.8-16.4 per million), and it did not vary over time. The prevalence of GIST was 
calculated from the incidence figures and the estimated death hazard function, and was 
found to be 129 per million; for patients with high-risk GIST, the prevalence was 
estimated to be 22.2 per million (paper I). The median age at presentation was 68 
years, and there was an equal gender distribution (paper II). GIST was occasionally 
found in young adults (only 4 out of 259 patients were younger than 30 years at 
presentation) in accordance with the results of Miettinen et al. (2005). Using 
information on the incidence of GIST and the age- and sex-specific distribution of the 
general population in our region, the age- and sex-specific incidence of GIST could be 
calculated (Fig. 3) (paper II). 
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In a recent US population-based study, a low annual incidence rate of GIST was 
reported: 7 cases per million inhabitants (Tran et al., 2005). Blanke et al. (2005) 
commented that one major limitation to this study was that only tumours reported to 
be malignant were included, which would lead to an underestimation of the true 
incidence. In line with our results, Tryggvason et al. (2005) reported an annual 
incidence of 11 cases per million inhabitants in an Icelandic population-based series 
(1990-2003) of similar design to that of ours. 
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Associated Malignancies 
Other malignancies (diagnosed before, after, or concomitant with GIST) were seen in 
almost one-third (27.8%) of the patients. Adenocarcinomas of the GI and urinary tract 
predominated. Interestingly, as many as 8 patients had NF1 or NE tumours (small cell 
lung carcinoma, carcinoid, pheochromocytoma) (Fig. 4). 
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A recent German single-centre study (Agaimy & Wuensch, 2005) demonstrated other 
malignancies associated with GIST-most commonly GI carcinomas-in 18 out of 97 
GIST patients (18.6%). These results and ours contrast with the findings of DeMatteo 
et al. (2000) and Crosby et al. (2001), who reported associated malignancies (before or 
concomitant with GIST) in only 6% and 5% of their respective study populations. This 
obvious discrepancy may relate to shorter follow-up and biased data from tertiary 
cancer centres with follow-up at other hospitals. 
The finding of 5 patients with NF1-associated GIST in our study is interesting, 
since there have been several smaller series indicating an association between NF 1 
and GIST (Cheng et al., 2004; Kinoshita et al., 2004; Yantiss et al., 2005). In an 
autopsy series of NF1 patients, GISTs were detected in up to one-third of the patients 
(Zöller et al., 1997). A recent study of 15 NF1 patients with GIST showed that these 
tumours were preferentially multicentric, of small intestinal origin, and devoid of KIT 
and PDGFRA mutations. NF1-GISTs were associated with a rather favourable 
prognosis; NE tumours (duodenal carcinoid or pheochromocytoma) were diagnosed in 
6 of the 15 patients (Andersson et al., 2005). 
Symptoms, Preoperative Investigations, Tumour Site, and Surgical Procedures 
In general, previous studies analysing surgical treatment, clinical course, and 
prognostic factors in GIST have suffered from methodological limitations. The early 
series were confounded by inclusion of non-GIST sarcomas. In several retrospective 
series, the tumour specimens had not been histopathologically reviewed and some 
studies only addressed subsets of tumours, e.g. "gastric or intestinal sarcomas" (Shiu et 
al., 1982; Akwari et al., 1978). Historically, the grading system has differed between 
studies, and the series from large referral centres were biased by having numerous 
patients with large and aggressive tumours (DeMatteo et al., 2000; Pierie et al., 2001; 
Singer et al., 2002). Papers I and II were the first to evaluate a large population-based 
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series of GIST patients with long-term follow-up during a time period when surgery 
was the only available treatment (Fig. 5): 
GIST-related symptoms were seen in 77% of the patients (paper II). GI bleeding 
(51%) and abdominal pain (32%) were the most common symptoms. It should be 
noted that it was more common to diagnose GIST incidentally than as a palpable mass. 
Almost half of the symptomatic GISTs were classified as high-risk, or overtly 
malignant. 
Preoperative investigation was performed in almost all symptomatic patients. 
Due to symptoms such as bleeding and abdominal pain, endoscopy was frequently 
used and often found to be diagnostic. However, diagnostic tumour tissue was only 
obtained in one-third of the endoscopic biopsies, which may reflect deep submucosal 
growth with indirect impression by the tumour. 
The most common tumour site was the stomach (55%), followed by the small 
intestine (37%). A few GISTs of retroperitoneal origin were seen, but no oesophageal 
GIST was diagnosed in our series. The tumour distribution was in accordance with the 
results of previous studies (DeMatteo et al., 2000; Miettinen & Lasota, 2001). 
The surgical procedures were predominantly gastric or intestinal resections. 
Only a minority of the patients underwent major surgical procedures, i.e. total 
gastrectomy or Whipple resection. 
% Preoperative investigation 
60-1 
Tumour site Surgery 
Fig. 5. Clinical features, diagnostic tools and treatment of GIST (n = 259). 
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The median tumour size in patients with clinically detected GIST was 8.9 cm (range 
1.0-35.0 cm). A solitary tumour was seen in 86% of the patients, and only a minority 
of these tumours invaded adjacent organs. This finding is in contrast to other non-
population-based studies that have reported approximately 30% invasive tumours at 
presentation (Nishida & Hirota, 2000). Very large tumours, measuring > 20 cm in 
diameter, may occur (Joensuu et al., 2002; DeMatteo et al., 2003). In our series, 12% 
of the patients had such large tumours. The type of clinical presentation was related to 
tumour size; small tumours (< 2 cm) were found incidentally during endoscopy, 
radiological imaging, or surgery for unrelated conditions, whereas larger tumours were 
diagnosed during work-up for abdominal pain, or palpable mass. Eight patients, 
including three with NF1, presented with multiple tumours. Twenty-nine patients 
(11%) presented with distant metastases and comprised the overtly malignant group. 
Although patients were treated at several different hospitals, complete (R0) 
resection was achieved in 85% of the patients (paper II); R0 resection was performed 
in 80% of the patients with high-risk tumours, but only in 17% of the patients with 
overtly malignant tumours. The radical resection rate in this study confirmed previous 
results from single institutions (DeMatteo et a l., 2000; Langer et al., 2003; Bucher et 
al., 2006). 
Recurrent Tumour Disease 
The recurrence rate was low in the entire series of patients, but the risk of recurrence 
differed significantly between risk groups. The rate of recurrent disease after R0 
resection was only 2% in the very low-, low- and intermediate-risk groups; these 
recurrent tumours were associated with negative prognostic factors: two patients had 
KIT exon 11 deletion, and one patient had high Ki67 max% (10%). In contrast, 
recurrent disease occurred in 62% and 100% of the R0-resected high-risk, or overtly 
malignant tumours, respectively; repeat surgery did not appear to influence survival 
(Table 4). 
The median tumour size and median Ki67 max% for the patients with recurrence 
was 12 cm (range 1.5-33 cm) and 25% (range 0.5^10%), respectively. The median 
time to first recurrence in patient s with high-risk, or overtly malignant, GIST was 19 
months (range 5-72 months) and 7 months (range 4-19 months), respectively. 
Recurrent tumours were thus larger, showed higher proliferation (Ki67 max%), and 
there was a higher proportion of KIT exon 11 deletions (53%) than non-recurrent 
tumours (22%) (P < 0.001). 
Survival and Prognostic Factors 
Estimation of overall survival for the different risk groups was performed using 
Poisson regression, which enables comparison with an age- and sex-matched normal 
population (paper I). Median overall survival for the patients with high-risk GIST and 
overtly malignant GIST was 40 months and 16 months, respectively, as compared to 
214 months for the age- and sex-matched normal population (P < 0.001). 
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Table 4. Clinical and histopathological data in 38 patients with low-, intermediate-, high-risk, and overtly 
malignant GIST with recurrent tumour disease after complete (RO) resection. 
Size Ki67 RG Kinase receptor mutation Site of TTFR No. Of Disease FU 
(cm) max% primary 
recurr. 
(mos) add. 
surg. 
status (mos) 
4 0.5 Low M552_Y553del (ex 11) Liv 55 0 TRD 57 
1.5 1 Low W557C K558_V559del (ex 11) Loc 24 1 NED 153 
4 10 Im WT Diss 26 0 TRD 28 
11 40 High WT Diss 5 0 TRD 6 
7.5 40 High L576P (ex 11) Diss 5 1 TRD 6 
8 10 High WT Liv 6 0 TRD 8 
10 40 High WT Diss 7 0 TRD 10 
9 25 High W557_K558del (ex 11) Liv 8 0 TRD 12 
10 30 High K550_K558del (ex 11) Diss 13 0 TRD 14 
30 25 High V559D (ex 11) Liv 8 0 TRD 14 
6 25 High WT Liv 12 0 TRD 14 
4 30 High V561D (ex 12) Liv 14 0 TRD 16 
3.5 25 High WT Diss 19 0 TRD 19 
13 5 High M552_V555del Q556K (ex 11) Liv 19 0 TRD 20 
17 1 High WT Liv 12 0 TRD 23 
16 0.5 High D572_D579dupl (ex 11) Loc 9 1 TRD 24 
20 25 High Y553_E554del (ex 11) Diss 5 2 TRD 27 
19 1 High Q556H W557_V560del (ex 11) Diss 13 0 TRD 28 
12 10 High WT Diss 18 0 TRD 28 
11 10 High K558_V560del (ex 11) Diss 13 2 TRD 39 
19 25 High W557_K558del (ex 11) Diss 12 4 TRD 42 
11 1 High K550I P551_E554del (ex 11) Loc 31 0 TRD 42 
26 10 High WT Diss 28 1 TRD 42 
16 1 High D579del (ex 11) Diss 17 0 TRD 45 
20 5 High V555_V559del (ex 11) Liv 15 1 TRD 46 
33 5 High W557_Q575del (ex 11) Liv 6 2 TRD 60 
15 10 High P551_E554del (ex 11) Liv 28 0 TRD 73 
15 0.5 High V560_N566del (ex 11) Diss 72 0 TRD 76 
4.5 15 High WT Diss 72 1 TRD 105 
5 25 High WT Diss 10 0 AWD 21 
12 10 High E554_W557del (ex 11) Liv 65 0 AWD 68 
6 10 High K558_V559del V560I (ex 11) Loc 16 5 AWD 100 
4 25 High WT Loc 12 1 NED 48 
20 10 OM D579_F591dupl (ex 11) Diss 4 1 TRD 6 
18 20 OM E554_V555del(ex11) Diss 7 0 TRD 8 
30 10 OM W557_E561del (ex 11) Diss 5 1 TRD 8 
17 10 OM W557C K558_V559del (ex 11) Diss 14 3 TRD 24 
30 10 OM WT Diss 19 2 TRD 38 
add, additional; AWD, alive with disease; Diss, disseminated disease (liver / peritoneal / omental / mesenteric 
/ pulmonary, and/or bone metastases); FU, follow-up; Im, intermediate; Liv, liver metastases only; Loc, local 
recurrence; mos, months; NED, no evidence of disease; OM, overtly malignant; recurr, recurrence; RG, risk 
group; surg, surgery; TRD, tumour-related death; TTFR, time to first recurrence; WT, wild-type. 
Univariate Analysis. In paper II, large tumour size, high mitotic rate, the presence of 
KIT exon 11 deletion, severe pleomorphism, high Ki67 max%, high age, short 
observation time after surgery, and non-RO resection (P < 0.001 in all variables) 
were all associated with recurrent tumour disease or tumour-related death (Table 5). 
Multivariate Analysis. In paper II, only large tumour size, high Ki67 max%, and the 
presence of KIT exon 11 deletion were independent predictors of recurrence. 
Independent predictors of tumour-related death were large tumour size, high Ki67 
max%, high age, short observation time after surgery, and non-RO resection. It 
should be noted that sex or tumour site (stomach vs. small intestine or colo-rectum) did 
not correlate with overall survival, although patients with gastric GIST had a 10% 
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lower risk ( lower hazard function) of dying than patients with small intestinal tumours 
(Table 5). 
Table 5. Prognostic factors for recurrent tumour disease in RO-resected GIST or tumour-related death in the 
entire series. 
Recurrent tumour disease 
(RO, n = 221) 
Tumour-related death 
(n = 259) 
Univariate 
analysis 
Multivariate analysis Univariate 
analysis 
Multivariate analysis 
Variable P P HR P P HR P P HR P P HR 
MR/50 hpf 1.16 < 0.001 3.18 0.390 0.48 <0.001 1.62 0.796 
Size (cm) 0.15 < 0.001 1.16 0.12 < 0.001 1.13 0.07 < 0.001 1.07 0.04 0.003 1.04 
Ki67max% 0.12 <0.001 1.13 0.12 < 0.001 1.12 0.07 <0.001 1.07 0.05 < 0.001 1.05 
«•/rex 11 
deletion 
1.42 <0.001 4.15 0.98 0.003 2.66 
R0 
resection 
-1.93 < 0.001 0.14 -0.85 0.008 0.43 
A hazard ratio (HR) of 2.66 for patients with KIT exon 11 deletion = 2.66 times greater risk for recurrence 
compared to patients without this mutation. A hazard ratio of 0.43 for patients with R0 resection = 57 (1-0.43 x 
100) % lower risk for tumour-related death compared to patients with R1/R2 resection. MR, mitotic rate. 
Previous studies have indicated several prognostic factors. In the NIH/NCI-workshop, 
tumour size and mitotic rate were considered to be the strongest predictors (Fletcher et 
al., 2002). In our study, we could confirm the importance of tumour size, but not 
mitotic rate. On the other hand, Ki67 max% (based on identification of "hot spots") 
had stronger predictive value than mitotic rate. DeMatteo et al. (2000) had earlier 
found advanced stage and large tumour size to be associated with poor survival. In 
contrast to our study, others have demonstrated significantly better survival for 
patients with gastric GIST (Emory et al., 1999; Miettinen & Lasota, 2001). 
The prognostic significance of KIT exon 11 mutations has been unclear. Some 
reports (Emst et al., 1998; Taniguchi et al., 1999; Kim et al., 2004) have shown that 
GISTs with KIT exon 11 mutations were associated with more aggressive behaviour 
than wild-type (WT) tumours, while other investigators (Sakurai et al., 1999; 
Andersson et al., 2002; Wardelmann et al., 2002) could not find such correlation. 
Interestingly, our study showed that patients with tumours with KIT exon 11 deletions 
had shorter recurrence-free survival than patients with other KIT mutations or WT 
tumours. Singer et al. (2002) had earlier demonstrated that a group of patients with 
KIT exon 11 deletions (single or combined with insertions) had a worse prognosis than 
patients with KIT exon 11 substitutions. 
There have been several studies reporting significantly improved survival rates 
after R0 resection v.s\ R1/R2 resection (Ng et al., 1992a; DeMatteo et al., 2000; Crosby 
et al., 2001). R2 resection was demonstrated to be a strong independent risk factor for 
tumour-related death in our study (paper II). The dismal prognosis for patients with 
high-risk, or overtly malignant, GIST in this study (paper II) corroborates the findings 
of previous large series (Ng et al., 1992b; Mudan et al., 2000; DeMatteo et al., 2000). 
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GIST Risk Score. The estimated influence of Ki67 max% on survival for fixed tumour 
size and the estimated influence of tumour size on survival for fixed Ki67 max% is 
shown in Fig. 6 A and B. Th e Poisson regression, based on analysis of tumour size, 
Ki67 max%, and overall surv ival, resulted in a risk score of 0.0486 < (tumour size in 
cm) + 0.0491 < (Ki67 max%), which was a linear combination defined by the 
variables size and Ki67 max%, and the beta-coefficients (0.0486 and 0.0491). Since 
both coefficients were almost identical (approximately 5%), a risk score could be 
calculated (i.e. the probability of dying within 5 years) depending on the percentile 
point of the risk score (size + Ki67 max%) and age at diagnosis (Fig. 6 C). 
40 (95%) 
30 (90%) Tumour 
Ki 67 maxVo size (cm) 15(75%) 
m 0,7 7 (median) 
5 25%) 
3 10%) 
population 
2 3 4 5 6 7 8 9  
Time since diagnosis (years) Time since diagnosis (years) 
40 45 50 55 60 65 70 75 
Age at diagnosis (years) 
A. B. C. 
Fig. 6. Estimated proportion of survivors according to Ki67 max% (A) and tumour size (B) and 
estimated probability of dying within 5 years according to various risk scores (tumour size in cm + 
Ki67 max%) and percentiles (C) in patients with clinically detected GIST (n = 251). Each % point 
increase in Ki67 max%, when tumour size fixed at 5 cm, was associated with a 5% increased risk of 
dying (A). Each 1-cm increase in tumour size, when Ki67 max% was fixed at 1%, was associated with 
a 5% increased risk of dying (B). 
Up to the median percentile (risk score = 7) , the estimated survival was no different 
from that of the normal population. In contrast, scores > 7 were associated with an 
increased risk of dying from the tumour disease within 5 years. The risk rapidly 
increased with increasing scores (Fig. 6 C). The risk score effectively stratified GIST 
patients into one group with excellent prognosis (< 7) and one group with poor 
prognosis (> 7). From a practical standpoint, any GIST larger than 6 cm, 
regardless of Ki67 max%, and any GIST with Ki67 max% > 5%, regardless of 
size, should be considered malignant. 
Recurrence-Free Survival. The Kaplan-Meier estimates for recurrence-free survival in 
GIST patients stratified according to risk group are shown in Fig. 7. The risk of 
recurrence was very high (median time to recurrence less than 20 months) for the 
high-risk or overtly malignant (median time less than 10 months) groups and 
extremely low for the very low-, low-, and intermediate-risk groups. The vast majority 
of primary recurrences in patients with high-risk GIST were diagnosed within three 
years of primary surgery, but 3 of 14 patients a t risk developed recurrence 3-6 years 
after the first inter vention. No recurrences were observed after 6 years (Fig. 7, Table 
4) (see Future Perspectives section). 
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Risk groups 
Fig. 7. Recurrence-free survival 
in GIST after complete (RO) 
resection stratified according to 
risk group (n = 221). P < 0.001, 
high-risk and overtly malignant 
vs. very low-, low- and 
intermediate-risk GIST 
(log rank test). No. at risk 
Very low 32 
Low 85 
Interm. 51 
High 48 
Overtly 5 
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Indication for Adjuvant Treatment with Imatinib 
From our results, it follows that adjuvant imatinib is not indicated in patients with very 
low-risk and low-risk GIST-and most probably not in patients with intermediate-risk 
tumours. Using our proposed GIST risk score, this corresponds to scores of < 7. In line 
with our results, disease-free patients with high-risk GIST with a follow-up of less 
than 6 years after surgery are at risk, high during the first 36 months (Fig. 7). All 5 
patients with overtly malignant GIST and R0 resection died rapidly from the disease 
(Fig. 7, Table 4). The results further support the inclusion criteria of ongoing 
prospective studies that preferably patients with high-risk GIST are candidates for 
adjuvant imatinib after R0 resection. In our large series, we identified 60 patients with 
high-risk GIST (16 out of 20 alive had no evidence of disease at the latest follow-up) 
and 29 patients with overtly malignant GIST (persistent disease in t he 4 patients still 
alive) (Fig. 8). Currently, all 8 patients (4 high-risk and 4 overtly malignant) with non-
resectable disease are on palliative treatment with imatinib. The 16 disease-free 
patients will be investigated with PET-CT. If resectable recurrence is found, repeat 
surgery will be performed. If R0 resection is achieved, a period of adjuvant imatinib 
will be offered to these patients (Fig. 8, Table 6). 
TRD 
n = 38 
Alive 
n = 20 
n = 16 
Palliative imatinib 
n = 3 
Palliative imatinib 
A. 
Overtly malignant 
n = 29 
Alive 
n = 4 
TRD 
n = 25 
Palliative imatinib 
n = 4 
B. 
Fig. 8. Management algorithm for identified survivors with high-risk (A) or overtly malignant 
GIST (B) from the entire series. TRD, tumour-related death; DOC, death of other causes; RD, 
recurrent disease; PD, persistent disease; NED, no evidence of disease. 
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Table 6. Clinical data and tumour characteristics in 16 RO-resectedpatients with high-risk GIST, alive 
and disease-free at the latest follow-up.  
Age (years) Size (cm) Ki67 max% Kinase receptor mutation FU (mos) 
51 12 5 WT 21* 
75 6 10 P577_F591dupl (ex 11) 21* 
70 15 0.5 WT 22* 
27 3.5 10 WT 24* 
69 5 5 K550_E554del, V555I (ex 11) 28* 
81 6 5 V559A (ex 11) 29* 
73 4.0 25 WT 48* 
63 14 1 l571_D579dupl (ex 11) 60* 
46 18 1 M552V (ex 11) 62* 
81 6 10 WT 87 
25 25 5 WT 91 
35 6 5 K558T, V559D (ex 11) 116 
69 11 5 Q556H, W557_L576del (ex 11) 126 
71 4.5 20 W557_K558del, V559F (ex 11) 137 
64 12 1 P551del, M552L (ex 11 ) 144 
72 12 5 V559A (ex 11) 151 
Median: 69 8.5 5 61 
del, deletion; dupl, duplication; FU, follow-up; WT, wild-type, 
"observation period shorter than 6 years. 
New Therapeutic Options Combining Surgical and Medical 
Treatment (paper III) 
Neoadjuvant Imatinib 
This early centre-based study which included 17 patients with high-risk, or overtly 
malignant, GIST was designed to study the efficacy of imatinib in different clinical 
settings. One patient with a very large non-resectable tumour was the first to receive 
neoadjuvant treatment with imatinib (400 mg once-daily over 3 months), which led to 
rapid tumour regression and facilitated standard surgical resection (Fig. 9). A pre-
treatment core-needle biopsy revealed a mixed spindled-epithelioid GIST, 
immunoreactive for KIT, and with a Ki67 index of 10%. The tumour had a KIT exon 
11 substitution (W557R). 
In the surgical specimen, extensive tumour necrosis was evident with few viable 
tumour cells; Ki67 index was zero. Fifty-five months aft er surgery, the patient is still 
on imatinib due to liver metastases, and is fully active. The liver metastases have been 
calcified. Repeat 18F-FDG-PET examinations show no radiotracer uptake. The 
neoadjuvant setting is very attractive, especially from the patient's point of view, since 
responding tumours may be removed with minimal sacrifice of normal tissues. To 
date, we have treated 7 patients in this manner; all primary tumours were removed 
with minimal sacrifice of adjacent organs and in one patient with recurrent tumour, 
abdominoperineal rectum amputation was avoided. One elderly patient with 
oesophageal GIST has shown marked tumour regression and will probably avoid a 
thoraco-abdominal procedure. The clinical value o f down-staging therapy, rendering 
primaries and metastases resectable, has later been shown by others (Scaife et al., 
2003; Hohenberger et al., 2003). 
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Fig. 9. ISF-FDG PET 
examinations before (a), after 3 
weeks (b), and after 3 months (c) of 
imatinib treatment. The high 
uptake of lsF-FDG seen in the 
tumour prior to imatinib treatment 
could not be detected after 3 weeks 
and 3 months of treatment. CT 
scans before (d), after 3 weeks (e), 
and after 3 months (f) of imatinib 
treatment. Over 3 months of 
imatinib treament, the tumour 
decreased in size from 35 to 18 cm. 
After 3 months of treatment not 
detectable at the L2 level (f). 
Corresponding T2- and Tr 
weighted MRI before (g) and after 
3 months (i) of treatment, showing 
tumour reduction. After 3 months 
of treatment, a GIST of small 
intestinal origin was completely 
resected, leaving adjacent 
structures intact (h). 
Adjuvant Imatinib 
Five patients received adjuvant treatment with imatinib after R0/R1 resection. Four of 
5 patients had KIT exon 11 mutations (deletions only: n = 3; substitution only: n = 1), 
and o ne patient was WT for exon 11. No patient given adjuvant imatinib developed 
recurrent tumour disease over 7-13 months of follow-up. There were no serious 
adverse effects from the drug; one patient developed transient minor oedema. In our 
consecutive series, we have now treated 21 patients with high-risk GIST with imatinib 
(400 mg once-daily over 12 months) after R0/R1 resection. The mean observation time 
is 35 months (SD 15 months). The recurrence-free survival for patients treated with 
adjuvant imatinib seems much improved relative to historic c ontrols from the pre-
imatinib era (papers I & II) (Fig. 10). 
Fig. 10. Recurrence-free 
survival in patients with high-
risk GIST treated with 
adjuvant imatinib after R0/R1 
resection (mean follow-up: 35 
months, SD 15 months) 
relative to historic controls 
treated solely with surgery. 
*** P < 0.0002 (log rank test). 
Patients treated 
with adjuvant 
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(n = 21) fœ 0.8 
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(n = 48) 
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Only one GIST treated with adjuvant imatinib has recurred (case 4 in paper III) (Fig. 
10); this patient underwent resections du e to local recurrence/peritoneal metas tases on 
several occasions. After the fifth tum our resection (right-sided hemihe patectomy), she 
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was treated with adjuvant imatinib for 12 months. Initial mutation analysis revealed a 
tumour lacking a KIT exon 11 mutation. Thirty-eight months after liver surgery, a 
solitary pulmonary metastasis was diagnosed and treated. She will not be further 
treated with imatinib since the tumour was verified WT for both KIT and PDGFRA. 
The role of adjuvant imatinib following repeat surgery for recurrent GIST has been 
reported by Lai et al. (2005). Of two patients, one remained tumour-free for 12 
months, while the other recurred 3 months after discontinuation of imatinib. No 
mutation analysis was performed and l8F-FDG-PET was not used during follow-up. 
Palliative Imatinib 
Eleven patients, all with metastatic non-resectable disease, received palliative 
treatment with imatinib. Seven of the 11 patients had KIT exon 11 mutations; deletions 
only (n = 4), or deletions combined with substitutions (n = 3). Of the 11 patients 
receiving imatinib in a palliative setting, 8 patients had partial tumour responses 
during a follow-up of 6-18 months. Two patients in this group died of myocardial 
infarction. Shortly before death, both showed progressive tumour disease on CT. 
There were no serious adverse effects by the drug in this group; three patients had 
minor oedema. 
The first patient treated with imatinib was a Finnish woman (Patient Zero) with 
widely metastatic GIST that was resistant to other therapies. The tumour had a KIT 
exon 11 mutation. Within a few weeks, the 18FDG-PET uptake was extinguished, and 
serial tumour biopsies during treatment showed myxoid degeneration and fibrosis 
(Joensuu et al., 2001). This remarkable therapeutic success led to rapid pha se I (va n 
Oosterom et al., 2001), II (Demetri et al., 2002), and III (Benjamin et al., 2003; 
Verweij et al., 2004) trials, which all confirmed the efficacy of imatinib treatment; 
partial responses were seen in 40-70% of the patients and stable disease in 15-30%. 
The randomised studies have not shown any difference in response induction between 
400 mg imatinib g iven once-daily as opposed to twice a day; however, the EORTC 
phase III trial demonstrated a significantly longer progression-free survival at the 
higher dose (Table 7). 
Table 7. Interim results in trials of imatinib as palliative treatment for metastatic GIST. 
Response (%) 
No. 
Trial Phase pts. 
Dose 
(mg/day) FU CR PR SD PD PFS 
EORTC 1 36 400-1000 > 10 mos - 51 31 8 82 
US II 73 400 52 mos 68 14 15 84 
multicentre 74 600 2 65 18 8 
EORTC III 470 400 25 mos 5 45 32 13 88 
472 800 6 48 32 9 108 
US III 361 400 14 mos - 43 32 - 80 
intergroup 360 800 41 32 82 
CR, complete response; EORTC, European Organisation for the Research and Treatment of Cancer; 
PD, progressive disease; PFS, progression-free survival (in weeks); PR, partial response; 
SD, stable disease. *randomised clinical trials. Modified from van derZwan & DeMatteo (2005). 
The median time to response, as judged by CT, was about three months. Metabolic 
responses, as judged by l8F-FDG-PET, were demonstrated within hours to days after 
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initiation of treatment (Joensuu & Dimitrijevic, 2001). Since the introduction of 
imatinib as treatment for metastatic GIST, the early clinical outcome has been 
dramatically improved; the 2-year overall survival for patients with metastatic disease 
is now approximately 70% (Verweij et al., 2004). 
Several studies have shown that the response to imatinib depends on the 
mutational status of KIT. Recent 4-year follow-up analysis of the US multicentre 
randomised phase II trial demonstrated that patients with metastatic GIST with KIT 
exon 11 mutations had a partial tumour response in 87% as opposed to 48% in 
tumours harbouring KIT exon 9 mutations and 0% in WT tumours, respectively. 
Accordingly, patients with tumours harbouring KIT exon 11 mutations had longer 
median event-free survival (> 100 weeks) than those with exon 9 mutations (< 28 
weeks) or WT tumours (< 14 weeks) (Blanke et al., 2006). These results corroborate 
our early series, in which all 9 responsive patients had a KIT mutation (8 exon 11 and 
one exon 9). 
New Imaging Options (paper IV) 
GIST can be a component of rare syndromes, i.e. Carney triad and NF1. In 1977, 
Carney et al. reported an association of multiple epithelioid gastric GIST, extra-
adrenal pheochromocytoma, and pulmonary chondroma in a small series of mainly 
young women. NF1 can be associated with several different malignancies, most 
commonly duodenal NE tumours and pheochromocytomas. GIST has been described 
as the most common GI manifestation in patients with NF1 (Fuller & Williams, 1991). 
However, the genetic basis for these associations is largely unknown (Table 8). 
Mutation analysis has revealed that all Carney-GISTs (Diment et al., 2005) and most 
NF1-GISTs (Takazawa et al, 2005) do not harbour KIT, or PDGFRA mutations. 
Table 8. Syndromes including GIST. 
Syndrome Locus name Gene locus Inheritance Gene 
Familial GIST Unknown Unknown AD KIT (JM) or PDGFRA 
GIST, hyperpigmentation, Unknown Unknown AD KIT (JM) 
urticaria pigmentosa 
GIST and dysphagia Unknown Unknown AD KIT (TK-2) 
Paraganglioma-GIST Unknown Unknown AD Unknown 
Carney triad Unknown Unknown Sporadic Unknown 
Neurofibromatosis type 1 NF1 17q11.2 AD NF1 
AD, autosomal dominant; JM, juxtamembrane domain; TK-2, tyrosine kinase 2 domain. 
Modified from Perry et al. (2006). 
In this study we reported two patients, one patient with complete Carney triad and one 
patient with NF1, in whom accurate diagnosis of both pheochromocytoma and GIST 
in the same patient was made by a 2-tracer PET technique using 18F-FDG for GIST 
and 1 'C-HED for pheochromocytoma. 
Carney Triad 
During follow-up of a 54-year-old female patient who presented with gastric GIST 39 
years ago, functional imaging using l8F-FDG for recurrent GIST and "C-HED for 
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pheochromocytoma demonstrated a liver tumour and two components of a left-sided 
juxta-adrenal tumour. High FDG uptake was seen in the liver tumour and the up per 
component of the juxta-adrenal lesion, indicating GIST. The lower juxta-adrenal 
portion had HED uptake only, thus indicating pheochromocytoma (Fig. 11). 
B Renal pelvis D Renal pelvis 
Fig. 11. A small GIST liver metastasis (A). This tumour and a synchronous GIST were visualised by 
,SF-FDG in the upper portion (B) of a time-glass shaped tumour adjacent to the left adrenal (C). The 
lower tumour portion was an extra-adrenal pheochromocytoma, imaged by "C-HED (D). 
Neurofibromatosis Type 1 
A 64-year-old male patient with NF1 had se vere attacks of hypertension and syncope 
due to pheochromocytoma. Urinary catecholamines and plasma CgA were markedly 
elevated. CT showed a left-sided adrenal tumour. At adrenalectomy, a large number of 
small intestinal tumours were seen, later proven to be G IST with no KIT mutation. 
With recent experience of the Carney patient, a 2-tracer PET was performed 
postoperatively, which demonstrated multiple FDG uptake in the abdomen and a small 
HED uptake in the residual right adrenal. After a 5-m onth period on imatinib, 2-tracer 
PET was repeated; the previously observed FDG uptakes were extinguished, but the 
adrenal HED uptake was unchanged. At second-look laparotomy, all residual G IST 
lesions were excised and a very small pheochromocytoma was enucleated with 
preservation of the adrenal cortex. 
Signalling through the MAP kinase pathway in WT-KIT was first demonstrated 
by Chian et al. (2001). This pathway may be operational in NF1-GIST, since NF1 
mutations result in constitutive RAS activation and increased signalling via the MAP 
kinase. This may be one explanation for the imatinib response seen in our patient with 
NF1-GIST with no KIT/PDGFRA mutation. 
To the best of our knowledge, this is the first study on a novel 2-tracer PET-
technique, which-with high precision-detected GIST and pheochromocytoma in 
patients with NE tumour syndromes. The small liver GIST in the Carney patient and 
the very small pheochromocytoma in the NF1 patient were not detected by CT/MR I. 
In a recent study by Trampal et al. (2004), it was concluded that nC-HED-PET is an 
imaging technique with high sensitivity and specificity in detecting 
pheochromocytomas. "C-HED-PET is one of the new functional imaging techniques, 
which awaits comparison with the most recent 6-[18F]-fluorodopamine-PET to detect 
small or multiple pheochromocytomas (Ilias et al., 2003). 
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Neuroendocrine Differentiation in GIST (paper V) 
The origin and differentiation of GIST has been under debate for decades. Today, 
GIST is considered to originate from ICC, or their precursor cells (Fig. 12). The KIT 
protein is expressed both by ICC and GISTs. Ultrastructural studies have demonstrated 
similarities between ICC and GISTs, e.g. the presence of cytoplasmic vesicles 
(Erlandson et al., 1996; Kindblom et al., 1998), also found in neurons and NE cells 
(Komuro, 1999). 
Fig. 12. Immunohistochemical demonstration 
of CD 117 (KIT,) in ICC, intercalated between 
intramural neurons and smooth muscle 
cells of the intestinal wall. 
NE function is defined by the presence of a regulated secretory pathway, which 
requires specific storage organelles. Two types of regulated sec retory pathways have 
been characterised. One pathway makes use of large dense-core vesicles (LDCV) 
containing e.g. chromogranins and vesicular monamine transporters (VMAT 1 & 2). 
The other pathway uses synaptic-like microvesicles (SLMV), e.g. synapsin 1, 
synaptophysin, synaptobrevin, and SV2 (Rindi et al., 2004). Expression of CgA and 
synaptophysin have been hallmarks of NE differentiation, but othe r synaptic vesicle 
proteins are also expressed in abundance in several NE tumour types, e.g. SV2, 
VMAT 1 & 2, and amphiphysin (Jakobsen et al., 2001 & 2002; Zanner et al., 2004). 
SLMV Proteins 
Our immunohistochemical study demonstrated positive staining for synapsin 1, SV2, 
amphiphysin, and synaptobrevin in the majority of low-risk profile GISTs and all 
high-risk profile GISTs (Table 9). 
Table 9. Immunohistochemical demonstration of SLMV proteins in GIST (n = 41). 
Marker Protein Low-risk profile High-risk profile 
(VL, L, Im), n= 29 (H, OM), n = 12 
SLMV Synapsin 1 25/26 8/8 
SV 2 27/29 12/12 
Amphiphysin 23/26 8/8 
Synaptobrevin 24/29 12/12 
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In positive tumours, the staining pattern was neurite- and bouton-like for synapsin 1, 
cytoplasmic and granular for SV2 and synaptobrevin, and cytoplasmic (perinuclear) 
for amphiphysin (Fig. 13). 
Fig. 13. Immunohistochemical 
demonstration of synaptic 
vesicle proteins in GIST. 
A. synapsin 1: strong staining of 
tumour cell neurites and 
boutons. 
B. SV2: moderate granular 
staining of cytoplasm. 
C. amphiphysin: moderate 
granular staining of cytoplasm 
(perinuclear). 
D. synaptobrevin: moderate 
granular staining 
of cytoplasm. 
Characterisations by western blot demonstrated SV2, amphiphysin, and synaptobrevin, 
with major bands of 75-100 kD, 85 kD, and 15 kD, respectively. Q-PCR demonstrated 
expression of SV2A, synapsin 1, amphiphysin, and synaptobrevin 1 & 2 in all GISTs 
(Fig. 14). 
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Fig. 14. Scatter plots of KIT-, and synaptic vesicle protein expression in GIST. Expression of SLMV 
markers (red) was higher than the expression of LDCV markers (blue). Ileal carcinoid and colorectal 
adenocarcinoma served as control tumours. Log-transformed gene expression ratios obtained from Q-
PCR analysis are plotted. Each dot represents data derived from one sample. Unfilled dots represent 
expression values below the detection limit. 
The median expression values for the SV2A and synaptobrevin 1 & 2 genes in GIST 
were similar to those observed in ileal carcinoids. The expression values for the 
synapsin 1 gene were two orders of magnitude lower than those observed in 
carcinoids. 
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LDCV Proteins 
Expression of LDCV proteins was demonstrated in a minority of GISTs. CgA and 
VMAT 1 & 2 were examined by immunohistochemistry, but only VMAT 1 could be 
demonstrated: a small number of tumour cells were stained in one-third of the 
tumours. Characterisation of LDCV proteins by western blot was negative for both 
VMAT 1 & 2 . Although Q-PCR analysis showed expression of CgA and VMAT 1 & 2 
in 5, 2, and 9 tumours out of 10 tumours, respectively, the expression values were 5, 4, 
and 3 orders of magnitude lower than those observed in carcinoids. 
Lack of Correlation between SLMV Expression and Clinicopathological 
Features 
There were no significant differences in the staining pattern, molecular size or 
expression levels of SLMV proteins when low-risk and high-risk profile GISTs were 
compared. Similarly, there were no significant differences in SLMV protein 
expression between GISTs with WT or mutated K1T/PDGFRA. 
NE differentiation has been documented in some non-endocrine tumours, e.g. 
prostatic carcinoma, breast carcinoma, and GI carcinoma (Hirano et al., 2005; van 
Krimpen et al., 2004; Grabowski et al., 2002). In contrast to GIST, the non-endocrine 
tumours show NE differentiation in only a subset of tumours. NE differentiation in 
prostatic carcinoma has been associated with poor prognosis (Di Sant'Agnese, 2001). 
However, in our GIST series, we were unable to detect any correlation between risk 
profile, mutational status of KIT/PDGFRA, and NE differentiation. 
This study shows that GISTs regularly express SLMV proteins, indicating that 
these tumours are related to the NE tumour family. High expression of G protein-
coupled receptors, e.g. somatostatin receptors, is a common finding in NE tumours and 
occasionally found in GIST (Montella et al., 2005). Recently, Reubi et al. (2004) 
demonstrated extremely high densities of several brain-gut peptide receptors in GIST, 
which may open other opportunities to treat patients with radiolabeled 
peptides/analogues in cases that are resistant to therapy. 
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CONCLUSIONS 
• The incidence of GIST (14.5 per million inhabitants per year) was found to be 
higher than previously estimated. The consensus risk stratification scheme has 
proven to be most useful. Prediction of prognosis for patients with GIST was 
simplified by a risk score based on the independent risk factors tumour size and 
proliferative index (Ki67 max%). 
• Complete (RO) resection and KIT exon 11 deletion were found to be independent 
prognostic factors. Imatinib in adjuvant setting is not indicated for patients with 
very low-, low-, or intermediate-risk GIST due to the good results obtained by 
surgery alone. 
• Treatment with imatinib in high-risk, or overtly malignant, GIST was found to be 
safe and effective, particularly in patients with KIT exon 11 mutations. Adjuvant 
treatment with imatinib seems promising, but long-term effects on survival must 
be evaluated in randomised clinical trials. In selected patients, neoadjuvant 
treatment can facilitate later surgical treatment. 
• A 2-tracer PET, using 18F-FDG and "C-HED, has the unique capacity to 
simultaneously detect GIST and pheochromocytoma in patients with NE tumour 
syndromes, e.g. Carney triad and NF1. 
• Both low- and high-risk GISTs regularly express synaptic vesicle proteins of 
SLMV type. One-third of the tumours also expressed the LDCV marker VMAT 
1. These features demonstrate a NE differentiation in a majority of GIST. 
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FUTURE PERSPECTIVES 
Clinical Trials 
Today, it is evident that patients with metastatic, disseminated, or unresectable GIST 
benefit from treatment with imatinib (paper III). Whether selected patients should be 
treated with imatinib prior to surgery, or with imatinib after complete (RO) resection of 
the primary tumour, is presently being evaluated in prospective American and 
European trials. For inclusion in these studies, information about K1T-/PDGFRA 
mutational status or objective response to imatinib, e.g. extinction of FDG uptake on 
PET, is not required. The results from our retrospective studies (papers I & II) 
demonstrate that adjuvant imatinib is not indicated for patients with very low-, low-, or 
intermediate-risk GIST due to the good results obtained by surgery alone. Our 
consecutive series (paper III) of patients with high-risk GIST treated with imatinib 
after R0/R1 resection (with mean follow-up of 35 months) indicate that these patients 
benefit from adjuvant treatment; the only recurrence observed was in a patient WT for 
both KIT and PDGFRA. 
In the international trials on adjuvant treatment, patients with low-risk GIST were 
excluded, but in the EORTC and ACOSOG Z9001 studies patients with intermediate-
risk tumours were included (Table 10). 
Table 10. Currently running trials combining surgery with neoadjuvant or adjuvant imatinib for GIST. 
Group/Trial Disease Setting Inclusion Dose 
RTOG S0132 Any Neoadjuvant Potentially resectable 
primary tumour a 5 cm or 
potentially resectable 
recurrent tumour a 2 cm 
600 mg/day x 8-10 
weeks preop. and 
600 mg/day x 24 
months postop. 
ACOSOG Z9000 Primary Adjuvant R0 resection and 
high-risk 
400 mg/day x 12 
months 
ACOSOG Z9001 Primary Adjuvant R0 resection and 
tumours 3 cm 
400 mg/day vs. 
placebo x 12 months 
SSG XVIII Primary with 
or without 
metastases 
Adjuvant R0 resection and 
high-risk 
400 mg/day x 12 
months vs. 36 months 
EORTC 62024 Primary Adjuvant R0 resection and 
intermediate-/high-risk 
400 mg/day vs. no 
treatment x 24 
months 
ACOSOG, American College of Surgeons Oncology Group; EORTC, European Organisation for Research 
and Treatment of Cancer; RTOG, Radiation Therapy Oncology Group; SSG, Scandinavian Sarcoma Group. 
Modified from van der Zwan & DeMatteo (2005). 
New Targeted Therapies 
Novel Medical Approaches 
Many patients with advanced GIST and long-term treatment with imatinib develop 
resistance. The median time to tumour progression is about 24 months (Antonescu et 
al., 2005). Four mechanisms for drug failure have been proposed: (1) acquisition of a 
secondary mutation in KIT or PDGFRA; (2) genomic amplification of KIT or 
PDGFRA with consequent kinase over-expression; (3) activation of an alternate 
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tyrosine kinase receptor with loss of KIT or PDGFRA oncoprotein expression and (4) 
functional resistance in vivo of tumours that are sensitive to imatinib in vitro (e.g. KIT 
exon 9 and WT KIT). Primary resistance is defined as rapid progression within the first 
6 months of treatment, usually at multiple sites. These tumours often exhibit WT KIT, 
KIT exon 9 mutations, or a D842V mutation of PDGFRA. Drug failure beyond 6 
months of treatment is defined as secondary resistance; only a few tumours continue to 
grow, while the majority of tumours are controlled by medication (Blay et al., 2005). 
In the case of resistance, the therapeutic options may include repeat surgery or other 
interventions (e.g. radiofrequency or cryo-laser ablation, or hepatic arterial 
embolisation), tyrosine kinase inhibitors with wider profile than imatinib, or targeting 
of other signalling pathway intermediaries (van der Zwan & DeMatteo, 2005). Some 
of the new drugs in the current clinical trials are the multikinase inhibitor AMG706, 
the mTOR inhibitor RAD001 and the protein kinase C inhibitor PKC412 (Fig. 15). 
We have treated 4 patients with imatinib resistance (three with a KIT exon 11 
mutation and one with WT) with the mTOR inhibitor rapamycin, which is usually 
used for immunosuppression in transplant patients. In the three patients with KIT 
mutations, the time to tumour progression was 6, 13, and 15 months, respectively. The 
patient with a WT tumour did not show any objective response. 
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Fig. 15. The downstream signalling pathways in GIST with drug targets. 
A novel tyrosine kinase inhibitor, currently in phase III clinical trials, is sunitinib 
malate (Sutent®; Pfizer Inc., New York, NY) (Fig. 15). This oral agent, which has 
activity against KIT, PDGFR, VEGFR, RET and FLT3, has yielded objective 
responses, or stable disease, in 26 of 48 évaluable patients with imatinib-resistance. It 
seems as if patients with KIT exon 9 mutations respond particularly well (79%) 
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(Demetri et al., 2004), which can make this drug a valuable complement to imatinib. 
We are currently evaluating sunitinib as treatment for metastatic, imatinib- and 
rapamycin-resistant GIST in a clinical trial (Protocol no. A6181036). All 4 patients, 
first treated with rapamycin upon tumour progression, now receive sunitinib. 
Cost and Quality 
The new generation of expensive targeted cancer drugs in combination with limited 
healthcare resources highlights the need for improved methods to estimate the benefits 
of different treatment strategies. One method of estimating the benefit of a certain 
therapy is to calculate its expected gain in quality-adjusted life years (QALYs). One 
QALY is defined as one year of perfect health. Comparisons can be made between 
different therapies, and priorities based on cost and quality can be made. A key 
question is whether the expected gain in QALYs outweighs the costs associated with 
the actual cost of the specific treatment. By using special Poisson regression models, 
which allow hazard functions to be estimated as continuous functions, we can derive 
and calculate these probabilities, expected length of life and expected gain in QALYs 
in detail and with precision from our large series of GIST (papers I &I I). 
GIST-a Neuroendocrine Tumour? 
GISTs express multiple synaptic vesicle proteins (paper V). These findings suggest 
that GISTs secrete hormones that may be used as markers in the diagnosis and follow-
up. Peptide receptors are important in the regulation of hormone secretion and have 
been demonstrated in both NE tumours and GISTs. We have observed individual 
patients with GISTs that were distinctly imaged by somatostatin receptor scintigraphy 
(Fig. 16). GISTs also express very high densities of other peptide receptors, e.g. 
bombesin subtype 2, vasoactive intestinal peptide subtype 2, and cholecystokinin 
subtype 2 (Reubi et al., 2004). 
Fig. 16. Somatostatin receptor scintigraphy 
visualising a GIST of small intestinal origin. 
High expression of somatostatin receptors in NE tumours has led to successful 
receptor-mediated radiotherapy using somatostatin analogues (Kwekkeboom et al., 
2003; Reubi, 2003). With access to suitable peptide analogues, receptor-mediated 
radiotherapy targeted to bombesin-, vasoactive intestinal peptide-, and cholecystokinin 
receptors may become a future alternative in patients with therapy-resistant GISTs. 
GiST-
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Gastrointestinal stromacellstumör (GIST) hör till gruppen mjukdelstumörer, dit även 
tumörer från ben, brosk, fett, muskulatur och blodkärl räknas. GIST kan utgå från hela 
magtarmkanalen men ses oftast i magsäck och tunntarm. Forskarna tror idag att GIST 
härstammar från förstadier till Cajal's celler, som ligger insprängda mellan muskel-
och nervceller i tarmväggen och ansvarar för magtarmkanalens motorik. Eftersom 
GIST inte går att behandla med cellgifter har kirurgi varit enda möjligheten att bota 
drabbade. Många patienter far dock återfall och dör av sin sjukdom trots upprepade 
operationer. GIST har varit en nyckfull tumör med svårbedömd prognos. I e tt försök 
att bättre kunna beskriva prognosen för en enskild tumör har ett system att skatta 
risken föreslagits, som baserar sig på tumörstorlek och celldelningsförmåga 
(analyserat som mitosfrekvens = antal tumörceller i delningsfas). Beroende på dessa 
egenskaper har tumörerna delats in i följande grupper: mycket låg, låg, intermediär 
och hög risk-tumörer. 
GIST har en receptor (mottagare för stimulering) kallad KIT på cellytan, som 
genom signalering till cellkärnan reglerar viktiga funktioner som celltillväxt och 
celldöd. Den gen (KIT), som kodar för denna mottagarmolekyl, har i majoriteten av 
GIST visat sig vara muterad, det vill säga genen förmedlar felaktig information som 
leder till överaktivering av KIT-receptorn med ökad celltillväxt/minskad celldöd till 
följd. Läkemedlet imatinib binder sig till KIT-receptorn och hämmar dess signalering, 
vilket visat sig vara effektivt för behandling av spridd eller icke-operabel GIST. 
Speciellt väl fungerar medicinen hos patienter med mutation i en specifik del (exon 
11 ) av KIT-genen. Nyttan av tilläggsbehandling med imatinib efter genomförd radikal 
operation av "risk-tumörer" samt imatinib-behandling för att krympa en stor tumör 
inför operation analyseras för närvarande i flera studier. Tumörutbredning påvisas 
vanligtvis med datortomografi eller magnetröntgen, men det har visat sig att positron-
emissions-tomografi (PET) med en radioaktivt märkt sockermolekyl, 
l8fluorodeoxyglukos (FDG), är en känslig funktionell metod för att tidigt utvärdera 
effekten av behandling. 
GIST-studier har hittills utgått från stora cancercentra vilket innebär att resultaten i 
stor utsträckning baserar sig på patientmaterial med större och mer aggressiva tumörer 
än vad man kan förvänta sig i en normalbefolkning. Syftet med denna avhandling har 
varit att (1) analysera hur vanligt GIST är i Västra Götalandsregionen samt att 
utvärdera den föreslagna riskskattningen; (2) utvärdera betydelsen av radikal operation 
och andra prognosfaktorer i ett stort populationsbaserat patientmaterial med lång 
uppföljningstid; (3) undersöka olika typer av behandling med imatinib, hur dessa kan 
kombineras med kirurgi samt utvärdera behandlingseffekten vid mutation i exon 11 i 
KIT-genen; (4) visa på det diagnostiska värdet av en ny typ av PET-undersökning hos 
patienter med GIST som del i syndrom innefattande olika tumörtyper; samt (5) 
utvärdera om GIST kan ha drag gemensamt med nervliknande hormonproducerande 
tumörer, så kallad neuroendokrin differentiering, eftersom GIST just utgår från Cajal's 
celler i tarmen. 
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Våra resultat visar att: 
(1) GIST är vanligare än tidigare beräknat; förekomsten av kliniskt upptäckt, GIST i 
Västra Götalands regionen är 14,5 patienter per en miljon invånare och år. Den 
gällande riskskattningen, baserad på tumörstorlek och mitosfrekvens, är väl 
användbar. Vi föreslår dock en modifierad riskskattning, som baseras på tumörstorlek 
och högsta observerade celldelning (Ki67 max%), som på ett enklare sätt skiljer ut 
GIST med god prognos. 
(2) Radikal operation och bortfallsmutation i KIT exon 11 är viktiga prognosfaktorer 
vid sidan av tumörstorlek och Ki67 max%. På grund av att patienter med mycket låg-, 
låg- och intermediär risk-GIST uppvisar synnerligen god prognos efter genomförd 
radikal operation, föreligger ingen indikation för behandling med imatinib för dessa 
patienter. 
(3) Imatinib-behandling av patienter med hög risk-GIST, eller uppenbart elakartad 
GIST, är säker och effektiv, särskilt om KIT exon 11-mutation föreligger. Behandling 
med imatinib efter kirurgi vid hög risk-GIST verkar lovande, men långtidseffekter 
måste studeras närmare i större studier. För patienter med mycket stor tumör kan 
förbehandling med imatinib leda till bättre resultat av en efterföljande operation. 
(4) En ny PET-undersökning användande 2 olika radioaktivt märkta spårmolekyler, 
deoxyglukos och hydroxyefedrin, kan samtidigt upptäcka såväl GIST som den 
neuroendokrina tumören feokromocytom hos patienter med neuroendokrina 
tumörsyndrom, det vill säga patienter som kan utveckla flera olika tumörtyper. 
(5) GIST uttrycker vissa synaptiska vesikelprotein som normalt förekommer i nerver 
och neuroendokrina tumörer. Detta fynd visar att GIST till viss grad har neuroendokrin 
differentiering. Vissa GIST kan vidare uttrycka peptider och peptidreceptorer, vilket 
kan ge möjlighet till strålbehandling, peptidanaloger (konstgjorda peptider) bundna till 
radioaktiva läkemedel binds då till dessa receptorer på tumörytan och ger en stråleffekt 
på tumören. 
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